FRM
ACAD icon

Fox Run Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Fox Run Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,666
Closed -$457K – 895
2026
Q1 		$457K Buy
21,666
+11,114
+105% +$266K 0.08% 478
2025
Q4 		$282K Buy
+10,552
New +$252K 0.04% 716
2025
Q2 		– Sell
-31,938
Closed -$530K – 817
2025
Q1 		$530K Buy
31,938
+6,516
+26% +$118K 0.08% 462
2024
Q4 		$466K Buy
+25,422
New +$410K 0.08% 459
2024
Q3 		– Sell
-20,302
Closed -$330K – 767
2024
Q2 		$330K Buy
+20,302
New +$328K 0.06% 537
2023
Q4 		– Sell
-23,477
Closed -$489K – 692
2023
Q3 		$489K Buy
+23,477
New +$638K 0.14% 270
2023
Q2 		– Sell
-63,707
Closed -$1.2M – 650
2023
Q1 		$1.2M Buy
+63,707
New +$1.21M 0.39% 30
2022
Q4 		– Sell
-14,920
Closed -$244K – 585
2022
Q3 		$244K Buy
14,920
+4,843
+48% +$78.4K 0.09% 422
2022
Q2 		$142K Sell
10,077
-14,023
-58% -$262K 0.07% 447
2022
Q1 		$584K Buy
+24,100
New +$583K 0.33% 63
2021
Q4 		– Sell
-12,027
Closed -$200K – 443
2021
Q3 		$200K Sell
12,027
-950
-7% -$18.3K 0.13% 390
2021
Q2 		$317K Buy
+12,977
New +$293K 0.29% 150
2020
Q3 		– Sell
-6,958
Closed -$334K – 158
2020
Q2 		$334K Buy
+6,958
New +$334K 0.44% 82
2019
Q4 		– Sell
-12,390
Closed -$446K – 366
2019
Q3 		$446K Buy
+12,390
New +$376K 0.41% 57
2018
Q3 		– Sell
-25,822
Closed -$394K – 540
2018
Q2 		$394K Buy
+25,822
New +$460K 0.13% 336
2017
Q2 		– Sell
-21,600
Closed -$743K – 610
2017
Q1 		$743K Buy
21,600
+10,200
+89% +$360K 0.3% 72
2016
Q4 		$329K Buy
+11,400
New +$302K 0.17% 257

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fox Run Management's ACAD Position: Q2 2026 in Review

Fox Run Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 21,666 shares — an estimated $457K sold.

Fox Run Management first reported a position in ACAD in Q4 2016 and held it in 17 quarters. The position peaked at $1.2M in Q1 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Fox Run Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 21,666 Acadia Pharmaceuticals shares in Q2 2026, an estimated $457K.
  • Fox Run Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 17 quarters.
  • Fox Run Management's Acadia Pharmaceuticals position peaked at $1.2M in Q1 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.